Evaluation of Autologous Tolerogenic Dendritic Cells in Highly Sensitized Patients Undergoing Kidney Transplantation

The study focuses on the use of **autologous tolerogenic dendritic cells (ATDC)** in patients who are highly sensitized and awaiting **kidney transplants**. The primary objective is to evaluate the efficacy and safety of ATDC in reducing sensitization levels in these patients, which is clinically relevant as it may increase the likelihood of successful transplantation and improve patient outcomes. No secondary objectives are provided in the available data.

The clinical trial involves participants who have undergone **kidney transplants**. The study population includes both male and female subjects, with an age range categorized as adults. The trial population was selected to include a vulnerable population, although specific selection criteria and the total number of participants have not been disclosed by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, and habits have not been specified. Key inclusion or exclusion criteria are not provided, indicating a focus on a broad demographic of individuals who have received kidney transplants.

The clinical trial is designed to evaluate the efficacy and safety of **autologous tolerogenic dendritic cells** in highly sensitized patients undergoing **kidney transplants**. This study is a Phase 3, randomized, double-blind, controlled trial, with an estimated recruitment start date of June 2, 2025, and an anticipated completion date of March 31, 2028. The trial will involve multiple study visits, beginning with an inclusion visit to screen potential participants for eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to either the treatment or control group, ensuring that neither the participants nor the investigators are aware of the group assignments to maintain the study's double-blind nature.

Participants will be required to attend regular follow-up visits throughout the trial duration to monitor their health status, assess the treatment's efficacy, and record any adverse events. These visits are crucial for collecting data on primary and secondary endpoints, which will contribute to the overall evaluation of the investigational product. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment.

The expected length of participant involvement will vary depending on individual response to treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure the collection of robust and reliable data, contributing to the understanding of the investigational product's potential benefits and risks in the context of kidney transplantation.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on June 2, 2025, with an estimated completion date of March 31, 2028. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, consistent with Phase 3 trial standards. The trial's design will ensure that data collection is systematic and adheres to rigorous scientific protocols, although specific tools or instruments for efficacy assessments are not mentioned. The trial's objective is to provide robust data on the efficacy of the intervention under investigation, contributing to the overall understanding of its therapeutic potential.